142 related articles for article (PubMed ID: 28119058)
1. Analysis of ribosomal protein S6 baseline phosphorylation and effect of tau pathology in the murine brain and human hippocampus.
Klingebiel M; Dinekov M; Köhler C
Brain Res; 2017 Mar; 1659():121-135. PubMed ID: 28119058
[TBL] [Abstract][Full Text] [Related]
2. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
Köhler C; Fuhr V; Dinekov M
Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
[TBL] [Abstract][Full Text] [Related]
4. S6 kinase phosphorylated at T229 is involved in tau and actin pathologies in Alzheimer's disease.
Sonoda Y; Tooyama I; Mukai H; Maeda K; Akiyama H; Kawamata T
Neuropathology; 2016 Aug; 36(4):325-32. PubMed ID: 26582459
[TBL] [Abstract][Full Text] [Related]
5. mTOR Hyperactivation in down syndrome hippocampus appears early during development.
Iyer AM; van Scheppingen J; Milenkovic I; Anink JJ; Adle-Biassette H; Kovacs GG; Aronica E
J Neuropathol Exp Neurol; 2014 Jul; 73(7):671-83. PubMed ID: 24918639
[TBL] [Abstract][Full Text] [Related]
6. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
7. mTor mediates tau localization and secretion: Implication for Alzheimer's disease.
Tang Z; Ioja E; Bereczki E; Hultenby K; Li C; Guan Z; Winblad B; Pei JJ
Biochim Biophys Acta; 2015 Jul; 1853(7):1646-57. PubMed ID: 25791428
[TBL] [Abstract][Full Text] [Related]
8. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
[TBL] [Abstract][Full Text] [Related]
10. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
[TBL] [Abstract][Full Text] [Related]
11. Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Aβ amyloidosis.
Köhler C; Dinekov M; Götz J
Neurobiol Dis; 2014 Nov; 71():169-79. PubMed ID: 25073087
[TBL] [Abstract][Full Text] [Related]
12. Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.
Guo JL; Narasimhan S; Changolkar L; He Z; Stieber A; Zhang B; Gathagan RJ; Iba M; McBride JD; Trojanowski JQ; Lee VM
J Exp Med; 2016 Nov; 213(12):2635-2654. PubMed ID: 27810929
[TBL] [Abstract][Full Text] [Related]
13. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
Tang Z; Bereczki E; Zhang H; Wang S; Li C; Ji X; Branca RM; Lehtiö J; Guan Z; Filipcik P; Xu S; Winblad B; Pei JJ
J Biol Chem; 2013 May; 288(22):15556-70. PubMed ID: 23585566
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
16. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.
Köhler C; Dinekov M; Götz J
Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633
[TBL] [Abstract][Full Text] [Related]
17. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
18. The use of mouse models to study cell-to-cell transmission of pathological tau.
Narasimhan S; Lee VMY
Methods Cell Biol; 2017; 141():287-305. PubMed ID: 28882308
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
Köhler C; Bista P; Götz J; Schröder H
Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
[TBL] [Abstract][Full Text] [Related]
20. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
